Blueprint Medicines
Maker of AYVAKIT, a KIT-inhibitor pill for systemic mastocytosis, now owned by Sanofi.
On the record
Checkpoint: Cogent files bezuclastinib NDA and FDA sets a review clock
The call
Blueprint's drug still leads its niche, but Cogent's cleaner-profile challenger is now moving through FDA review under Sanofi's ownership.
Blueprint Medicines developed AYVAKIT, a drug that stops a specific cancer protein called KIT. It was the first and only approved drug of its kind across the full range of KIT-driven cancers, giving it an advantage. Now that Sanofi bought the company in July 2025, Blueprint is no longer independent, so there is no separate stock upside anymore. However, a competing company called Cogent Biosciences is bringing bezuclastinib, which may work better for some patients and could capture part of the market Blueprint was counting on. The big question is whether Cogent's drug wins FDA approval in late 2025 or 2026 and how many patients choose it over AYVAKIT, which could force Blueprint to grow slower than the two-billion-dollar target it had set for 2030.
Why
01
AI pressure: None apparent. No AI product threatens AYVAKIT sales; Blueprint instead uses VantAI's AI models to hunt for new molecular-glue drugs. Could AI do the core job? Unlikely.
02
Bigger players: Cogent Biosciences (bezuclastinib). Cogent's rival KIT inhibitor got FDA Breakthrough Therapy status in Oct 2025 and plans an NDA filing by year-end 2025. Could a giant copy it? No, they are blocked.
03
What protects it. AYVAKIT is the only drug approved across the full mastocytosis spectrum, plus Sanofi's cash and rare-disease sales reach.
What would change this call
Cogent Biosciences files bezuclastinib NDA with FDA by year-end 2025. Shows a credible AYVAKIT rival is nearing market entry.
FDA approval decision on bezuclastinib in 2026, expected Q2-Q3. Approval would create the first head-to-head KIT inhibitor competitor to AYVAKIT.
Sanofi's quarterly filings show AYVAKIT revenue growth slowing below 2025 guidance of $700-720M. Would indicate early competitive or integration pressure on Blueprint's core drug.
FDA approval decision on bezuclastinib in 2026, expected Q2-Q3. Approval would create the first head-to-head KIT inhibitor competitor to AYVAKIT.
Sanofi's quarterly filings show AYVAKIT revenue growth slowing below 2025 guidance of $700-720M. Would indicate early competitive or integration pressure on Blueprint's core drug.
Key numbers
- AYVAKIT 2024 global revenue: $479.0M
- Q1 2025 revenue up 61% YoY to $149.4M
- Sanofi buyout: $129/share cash, ~$9.1B total
Named risks
- Cogent's bezuclastinib could win FDA approval with a cleaner CNS profile and erode non-advanced SM share.
- Blueprint no longer reports standalone financials, reducing visibility into AYVAKIT performance inside Sanofi.
- Reaching the $2B by 2030 AYVAKIT target requires roughly 20% penetration of a small ~25,000-patient U.S. population.
- Sanofi capital allocation to other deals like Dynavax could divert investment from legacy Blueprint pipeline.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Cogent Biosciences | contesting | Bezuclastinib got FDA Breakthrough Therapy Designation Oct 20, 2025; NDA planned year-end 2025 |
| Novartis | gaining on | Midostaurin (Rydapt) remains legacy standard-of-care rival in advanced SM since 2017 approval |
Questions people ask
- Is Blueprint Medicines still a publicly traded company?
- No. Sanofi completed its acquisition of Blueprint Medicines on July 18, 2025, and BPMC stock was delisted from Nasdaq the same day. Blueprint now operates as an indirect wholly owned subsidiary of Sanofi rather than an independent public company.
- How much did Sanofi pay for Blueprint Medicines?
- Sanofi paid $129.00 per share in cash plus a Contingent Value Right worth up to $6.00 tied to BLU-808 milestones through June 30, 2032, totaling about $9.1B cash and up to $9.5B fully diluted, per the June 2, 2025 merger agreement.
- Is Blueprint Medicines profitable?
- As an independent company, Blueprint reported total 2024 revenue of $508.8M, including $479.0M from AYVAKIT, up from $249.4M in 2023. It no longer reports standalone financials since becoming a Sanofi subsidiary on July 18, 2025, so current profitability is folded into Sanofi's consolidated results.
- Who is Blueprint Medicines' biggest competitor now?
- Cogent Biosciences is the closest direct threat. Its rival KIT inhibitor bezuclastinib received FDA Breakthrough Therapy Designation on October 20, 2025, with an NDA submission planned by year-end 2025, targeting the same systemic mastocytosis and GIST markets as Blueprint's AYVAKIT.
- Could AI replace what Blueprint Medicines does?
- Not the regulated core. AYVAKIT's value rests on FDA-approved label exclusivity and proprietary trial data from the PIONEER, EXPLORER, and PATHFINDER studies, which AI cannot replicate without new clinical trials. AI tools like VantAI's Neo-1, added via a May 2025 collaboration, only assist early discovery, not approval.
- What is Blueprint Medicines' revenue growth target for AYVAKIT?
- Management set a long-term target of $2B in annual AYVAKIT revenue by 2030 against an estimated $4B peak systemic mastocytosis franchise opportunity, based on roughly 25,000 diagnosed U.S. patients and about 20% market penetration, stated as of May 1, 2025.
Timeline
- 2026-01-29Sanofi FY2025 results show launch products including Ayvakit lifted launch sales 49.4% to EUR1.1B
- 2025-10-20Cogent Biosciences' bezuclastinib gets FDA Breakthrough Therapy Designation, NDA planned year-end 2025
- 2025-07-18Sanofi completes acquisition; Blueprint Medicines delisted from Nasdaq
- 2025-06-02Sanofi announces deal to acquire Blueprint for $129/share plus up to $6 CVR
- 2025-05-21Blueprint expands AI drug discovery collaboration with VantAI using Neo-1 model
- 2025-05-01Q1 2025 AYVAKIT revenue up 61% YoY to $149.4M; FY2025 guidance raised to $700-720M
- 2025-02-13Blueprint reports FY2024 total revenue of $508.8M, AYVAKIT revenue $479.0M
- 2023-05AYVAKIT approved for indolent systemic mastocytosis
- 2021-06AYVAKIT approved for advanced systemic mastocytosis
- 2020-01AYVAKIT approved for PDGFRA D842V-mutant GIST
Revision history
24 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Blueprint Medicines 8-K, Merger Agreement (2025-06-02)
- Sanofi completes acquisition of Blueprint Medicines (2025-07-18)
- Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results (2025-02-13)
- Blueprint Medicines Reports First Quarter 2025 Results and Raises Guidance (2025-05-01)
- BPMC Q1 2025 Earnings Report (2025-05-01)
- Blueprint Medicines (BPMC) Number of Employees (2024-12-30)
- EX-99.1 (Sanofi/Blueprint) (2025-07-18)
- Blueprint Medicines and VantAI to advance novel therapies with expanded agreement (2025-05-21)
- Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib (2025-10-20)
- Sanofi completes acquisition of Blueprint Medicines (2025-07-17)
- Sanofi FY2025/Q4 results, strong sales and EPS growth (2026-01-29)
- Blueprint Medicines Corporation (BPMC) Company Profile & Facts (2025-05-01)